HC clarifies import rules for ayurvedic drugs in India
Chennai: Madras high court has clarified that although no licence is required to import ayurvedic drugs into India, it is necessary that the imported products conform to the standards prescribed for similar products manufactured in India.
Tired of too many ads? go ad free now
"For such a purpose, it is necessary that such consignments be tested by one of the laboratories accredited to the Central Drugs Standard Control Organisation (CDSCO)," Justice Senthilkumar Ramamoorthy said. This process shall be overseen by the State Licensing Authority, which is the licensing authority for the manufacture of ayurvedic drugs. All expenses related to such testing shall be borne by the importer, the court stated.
The court passed the order while disposing of a plea moved by Axeon Marketing India, the importer of 'Axe Brand Medicated Oil' from Singapore. They approached the court challenging the notices for alleged violation of the Drugs and Cosmetics Act. It argued that although the definition of "drug" read with the definition of ayurvedic, siddha, or unani drug indicates that the statute applies to ayurvedic drugs, the provisions related to the import of drugs are inapplicable to ayurvedic drugs.
The import policy provides that the import of ayurvedic drugs may be undertaken "free", without a licence, the petitioner said. Opposing the contentions, the import commissionerate submitted that while the act and the rules deal with the manufacture of ayurvedic drugs in India and prescribe licensing requirements in relation thereto, licensing requirements have not been specifically prescribed for ayurvedic drugs.
In the absence thereof, the import of ayurvedic drugs is prohibited.
MSID:: 122269759 413 |
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New Indian Express
21 hours ago
- New Indian Express
Licence must for importing ayurvedic drugs: Madras HC
CHENNAI: The Madras HC has ruled that licence shall necessarily be obtained for importing ayurvedic drugs and suggested the centre make necessary modifications in the existing rules in order to prescribe standards and prepare appropriate forms for granting import licences. Justice Senthilkumar Ramamoorthy, in a recent order on a petition filed by an importer of Axe Medicated Oil seeking directions to clear his consignments from Singapore, said there is a strong public interest element, specifically public health element, in relation to the import of drugs. Stating that the statute clearly applies to ayurvedic drugs and does contain a prohibition or exemption in respect of import of ayurvedic drugs a precondition for clearances, the judge said it is necessary that the products imported by the petitioner shall be in conformity with the standards prescribed for similar products manufactured in the country.
Time of India
a day ago
- Time of India
HC clarifies import rules for ayurvedic drugs in India
Cleared - mani Chennai: Madras high court has clarified that although no licence is required to import ayurvedic drugs into India, it is necessary that the imported products conform to the standards prescribed for similar products manufactured in India. Tired of too many ads? go ad free now "For such a purpose, it is necessary that such consignments be tested by one of the laboratories accredited to the Central Drugs Standard Control Organisation (CDSCO)," Justice Senthilkumar Ramamoorthy said. This process shall be overseen by the State Licensing Authority, which is the licensing authority for the manufacture of ayurvedic drugs. All expenses related to such testing shall be borne by the importer, the court stated. The court passed the order while disposing of a plea moved by Axeon Marketing India, the importer of 'Axe Brand Medicated Oil' from Singapore. They approached the court challenging the notices for alleged violation of the Drugs and Cosmetics Act. It argued that although the definition of "drug" read with the definition of ayurvedic, siddha, or unani drug indicates that the statute applies to ayurvedic drugs, the provisions related to the import of drugs are inapplicable to ayurvedic drugs. The import policy provides that the import of ayurvedic drugs may be undertaken "free", without a licence, the petitioner said. Opposing the contentions, the import commissionerate submitted that while the act and the rules deal with the manufacture of ayurvedic drugs in India and prescribe licensing requirements in relation thereto, licensing requirements have not been specifically prescribed for ayurvedic drugs. In the absence thereof, the import of ayurvedic drugs is prohibited. MSID:: 122269759 413 |
The Hindu
a day ago
- The Hindu
KCS notified as authorised body to inspect medical devices manufacturing facilities
The Central Drugs Standard Control Organisation (CDSCO), under the Ministry of Health and Family Welfare, has notified the Kalam Institute of Health Technology (KIHT) Certification Services (KCS) as the State's first regulatory body authorised to inspect the manufacturing facilities for Class A and Class B medical devices, according to a release here. Among the 14 such notified bodies nationwide, KCS is the only one operational in Andhra Pradesh and Telangana, marking a milestone in the region's quality management capabilities. Founded in July 2017, the KIHT, located on the AMTZ campus, is a Central government project supported by the Department of Biotechnology. It promotes and supports innovations in medical technologies through research and development, industry promotion, policy-making and knowledge repository. Founded in April 2022, the KCS is accredited by the National Accreditation Board for Certification Bodies (NABCB). The organisation offers comprehensive services, including ISO- 13485 certification, quality systems audit, risk management training, and CE‐mark consultancy — making it a full service hub for manufacturers seeking to meet global regulatory standards. This approval brings immediate benefits to domestic manufacturers, particularly the MSMEs, by eliminating the need for audits outside the State — resulting in significant time and cost savings. It also reinforces Andhra Pradesh's MedTech credentials, supporting national campaigns like 'Make in India' and 'ACI manufacturing', while making the region highly attractive for future investments. This significant milestone empowers KCS to conduct independent regulatory audits for medical device manufacturers in accordance with the Medical Devices Rules (MDR)-2017 for Class A (low risk) and Class B (moderate risk), the release added, while underscoring the State's reputation as a business-friendly hub, ready to meet rising global demand in healthcare.
